A snapshot of the board as of our publication date — the shortage aftermath, the channel wars, the pipeline — with links into the evidence library for depth. Dated content by design: check the linked files and primary sources for anything that may have moved since.
The shortage era is officially over; its aftermath isn’t
The FDA resolved the tirzepatide shortage in late 2024 and semaglutide’s in early 2025, which legally closed the mass-compounding window that defined 2022–2024. What followed — the enforcement wave, the “personalized dosing” workaround theories, the state-board actions — is the contested landscape our legal-status file maps in detail. The short version for shoppers: the compliant lanes narrowed, the marketing did not, and the gap between those two facts is where most of this market’s risk now lives.
The channel war repriced everything
Manufacturer direct-to-patient channels — LillyDirect’s Zepbound vials, NovoCare’s Wegovy pharmacy — kept expanding dose availability and pressing self-pay prices downward through 2025–2026, resetting what “cash price” means for brand product. Every figure moves, so we publish none here: the true-cost method plus the manufacturers’ own current pages beat any recap’s snapshot. The strategic read: brand’s floor keeps dropping toward compounded’s ceiling, which squeezes exactly the providers our ledger tracks — and explains much of the marketing volatility readers keep asking about.
Partnership churn as a category signal
The Hims–Novo collapse of June 2025 remains the emblematic event: brand access granted, then revoked over compounding conduct — followed by the pivot to “personalized” compounded product that our comparison files discuss structurally. Ro’s brand-vial dispensing arrangement points the other direction. The pattern worth watching isn’t any one deal; it’s that manufacturers are now actively sorting telehealth into compliant partners and adversaries, and provider business models are re-forming around which side of that sort they land on.
Pipeline: the next two years took shape
Orforglipron’s positive phase-3 oral results in 2025 set up the first pill-first mass-market moment — timeline and caveats in the oral file. CagriSema’s readouts recalibrated “next-gen” expectations rather than exploding them; retatrutide’s triple-agonist data kept the ceiling conversation alive (preview file). Meanwhile the approved drugs kept collecting indications — sleep apnea, cardiovascular risk, kidney disease — which is quietly the bigger story: the class is becoming multi-condition medicine, and coverage logic is reorganizing around that fact.
Generics arrived at the back gate
Liraglutide’s generic era began in earnest — the first true price-curve crack in the class — with the practical implications (and honest efficacy context) covered in the STEP 8 file. Nobody’s weekly flagship goes generic for years; watching how payers and cash channels use the daily generic anyway is one of 2026’s more interesting subplots.
What we’re doing about all of it
Our job in a moving market is unchanged: verify prices at checkout, date every figure, archive every snapshot, and keep the evidence library ahead of the marketing. The verification queue order stands; the next recap lands when the board moves enough to warrant one.